GENE ONLINE|News &
Opinion
Blog

Roche
Belharra Therapeutics Exits Stealth With $130 Million And A Genentech Deal
2023-01-05
Roche’s Lunsumio Lands FDA Approval for Pretreated Follicular Lymphoma
2022-12-26
Canada Authorizes Roche’s Polivy as First-Line Lymphoma Treatment
2022-11-27
Roche’s Gantenerumab Fails Trials In Alzheimer’s Disease
2022-11-15
Roche Clocks Clinical Win as it Eyes Additional Vabysmo Indication
2022-10-27
Genentech Unveils Positive Two-Year Data For Spinal Muscular Atrophy Drug
2022-10-13
Roche’s Newly Approved Companion Diagnostic May Open Treatment Options for HER2-low Patients
2022-10-06
Roche Buys Good Therapeutics For $250 Million Upfront, Obtains Immune Stimulating Antibody Conjugate Program
2022-09-08
Roche Dives Deeper into Off-The-Shelf Cell Therapies in Poseida Partnership
2022-08-04
Cancer Immunotherapy Phase III Trial Yields Positive Results
2022-08-02
Roche Bags Fast Track Label for New Alzheimer’s Diagnostic
2022-07-21
Roche Offers Up to $1 Billion for Avista to Develop Eye Disease Vectors
2022-07-20
Roche Receives Rights to Ionis’ Antisense Kidney Disease Drug for $55 Million
2022-07-12
Roche’s Non-Hodgkin Lymphoma Drug Could See Accelerated Approval By December
2022-07-07
Europe Okays Roche’s CAR-T Competitor for Blood Cancer
2022-06-09
1 2 3 6
LATEST
NDA for Biogen-Sage’s Zuranolone Accepted by FDA, Marking Another Step Forward in Depression Drug Development
2023-02-07
BMS Returns $475 Million Cancer Asset To Dragonfly Therapeutics
2023-02-07
FDA Expands Approval For Takeda’s Takhzyro To Prevent Hereditary Angioedema Attacks
2023-02-06
Abbott’s New Technologies for Arrhythmia Treatment Secure FDA and European Approval
2023-02-04
First Human Trial for Marburg Virus Vaccine Reports Success
2023-02-03
Karuna Licenses Goldfinch’s Mood Disorder Candidates For Potential $535 Million
2023-02-03
Novel Bioengineered Wearable Edgeless Skin Brings Hope to Revolutionize Plastic and Reconstructive Surgery
2023-02-03
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!